Adage Capital Partners Gp, L.L.C. Ardelyx, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

$54.6 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$3.29 - $6.64 $987,000 - $1.99 Million	300,000 Added 13.04%	2,600,000 $16.1 Million
Q3 2023 Nov 14, 2023	BUY	$3.3 - $4.83 $7.59 Million - $11.1 Million	2,300,000 New	2,300,000 $9.38 Million
Q1 2023 May 15, 2023	BUY	$2.68 - $4.79 $1.07 Million - $1.92 Million	400,000 Added 24.24%	2,050,000 $9.82 Million
Q4 2022 Feb 14, 2023	SELL	$1.22 - $2.85 $2.87 Million - $6.7 Million	-2,350,000 Reduced 58.75%	1,650,000 $4.7 Million
Q3 2022 Nov 14, 2022	BUY	$0.59 - $1.44 $2.36 Million - $5.76 Million	4,000,000 New	4,000,000 $4.76 Million
Q3 2021 Nov 15, 2021	SELL	$1.27 - $8.17 $1.91 Million - $12.3 Million	-1,500,000 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$6.55 - $8.98 $18 Million - $24.7 Million	-2,754,892 Reduced 64.75%	1,500,000 $11.4 Million
Q1 2021 May 17, 2021	SELL	$6.1 - $7.69 $4.55 Million - $5.73 Million	-745,108 Reduced 14.9%	4,254,892 $28.2 Million
Q2 2020 Aug 14, 2020	SELL	$5.37 - $8.11 $1.42 Million - $2.14 Million	-263,685 Reduced 5.01%	5,000,000 $34.6 Million
Q1 2020 May 15, 2020	SELL	$4.35 - $8.79 $1.89 Million - $3.82 Million	-434,657 Reduced 7.63%	5,263,685 $29.9 Million
Q4 2019 Feb 14, 2020	BUY	$4.23 - $8.29 $7.18 Million - $14.1 Million	1,698,342 Added 42.46%	5,698,342 $42.8 Million
Q4 2018 Feb 14, 2019	BUY	$1.66 - $4.16 $830,000 - $2.08 Million	500,000 Added 14.29%	4,000,000 $7.16 Million
Q3 2018 Nov 14, 2018	BUY	$3.75 - $4.65 $1.88 Million - $2.33 Million	500,000 Added 16.67%	3,500,000 $15.2 Million
Q2 2018 Aug 14, 2018	BUY	$3.7 - $5.8 $11.1 Million - $17.4 Million	3,000,000 New	3,000,000 $11.1 Million

Others Institutions Holding ARDX

# of Institutions

214

Shares Held

141M

Call Options Held

1.08M

Put Options Held

View Full List

About ARDELYX, INC.

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $854M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

More about ARDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.

Account